Clinical trial / 2022
Nicotinamide riboside supplementation was well tolerated and increased cerebral NAD levels in patients with Parkinson's disease.
A double-blind phase I trial evaluated oral nicotinamide riboside (NR; 1,000 mg daily) versus placebo for 30 days in 30 newly diagnosed, treatment-naive Parkinson's disease patients. NR was well tolerated and caused a significant, though variable, increase in cerebral NAD levels and related CSF metabolites. Patients with increased brain NAD levels showed altered cerebral metabolism that was linked to mild clinical improvement. NR also upregulated processes linked to mitochondrial, lysosomal, and proteasomal function in blood and/or muscle, and lowered inflammatory cytokines in serum and CSF.
- Study type
- Double-blind randomized phase I clinical trial
- Who was studied
- 30 newly diagnosed, treatment-naive Parkinson's disease patients
- What was measured
- Safety, cerebral NAD levels, cerebral metabolism, inflammatory cytokines, and related metabolic and clinical changes
THE PAPER
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Brakedal B, Dölle C, Riemer F, Ma Y, Nido GS, Skeie GO, Craven AR, Schwarzlmüller T, Brekke N, Diab J, Sverkeli L, Skjeie V, Varhaug K, Tysnes OB, Peng S, Haugarvoll K, Ziegler M, Grüner R, Eidelberg D, Tzoulis C. Cell Metab, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.